Outcome
|
Atorvastatin
40mg Users
(N= 475)
n (%)
|
Atorvastatin 80mg Users
(N= 151)
n (%)
|
Adjusted Hazard Ratio
95% CI
|
P-value
|
Secondary effectiveness endpoints at 1 month |
|
|
|
|
All-cause mortality
|
0
|
2 (1.3)
|
1 (0.03-35.2)
|
1.0
|
Cardiovascular mortality
|
0
|
2 (1.3)
|
1 (0.03-35.2)
|
1.0
|
Fatal or non-fatal stroke
|
0
|
0
|
|
|
Fatal or non-fatal ACS
|
5 (1.1)
|
0
|
1 (0.10-9.60)
|
1.0
|
Coronary revascularization
|
2 (0.4)
|
0
|
1 (0.03-37.45)
|
1.0
|
Stent thrombosis
|
0
|
0
|
|
|
Stent restenosis
|
0
|
0
|
|
|
Secondary effectiveness endpoints at 12 months |
|
|
|
|
All-cause mortality
|
1 (0.2)
|
1 (0.7)
|
1 (0.02-41.29)
|
1.0
|
Cardiovascular mortality
|
1 (0.2)
|
1 (0.7)
|
1 (0.02-41.29)
|
1.0
|
Fatal or non-fatal stroke
|
4 (0.8)
|
0
|
–
|
0.577*
|
Fatal or non-fatal ACS
|
11 (2.3)
|
4 (2.6)
|
0.79 (0.18-3.41)
|
0.749
|
Coronary revascularization
|
5 (1.1)
|
3 (2.0)
|
0.62 (0.09-4.31)
|
0.632
|
Stent thrombosis
|
0
|
0
|
|
|
Stent restenosis
|
2 (0.4)
|
1 (0.7)
|
1 (0.02-66.3)
|
1.0
|
Lipid lowering outcomes |
|
|
|
|
LDL-C < 70mg/dLa
|
114 (24.0)
|
34 (22.5)
|
–
|
0.812**
|
Reduction of LDL-C by 50%a
|
72 (15.2)
|
32 (21.2)
|
–
|
0.022**
|
Safety outcomes |
|
|
|
|
Myopathy
|
4 (0.8)
|
1 (0.7)
|
–
|
1.0*
|
ALT > 3 ULN
|
4 (0.8)
|
1 (0.7)
|
–
|
1.0*
|
AST > 3 ULN
|
3 (0.6)
|
0
|
–
|
1.0*
|
Rhabdomyolysis
|
0
|
0
|
|
|
Adverse drug event requiring statin discontinuation
|
3 (0.3)
|
0
|
–
|
1.0*
|
*P-value was obtained using Fisher’s Exact test;
**P-value was obtained using Chi-square test;
aMissing data for ~60% of study
participants in both arms; ACS: acute coronary syndrome;
LDL-C: low-density lipoproteins cholesterol; ALT:
alanine aminotransferase; AST: aspartate aminotransferase |
*P-value was obtained using Fisher’s Exact test;
**P-value was obtained using Chi-square test;
aMissing data for ~60% of study
participants in both arms; ACS: acute coronary syndrome;
LDL-C: low-density lipoproteins cholesterol; ALT:
alanine aminotransferase; AST: aspartate aminotransferase |
*P-value was obtained using Fisher’s Exact test;
**P-value was obtained using Chi-square test;
aMissing data for ~60% of study
participants in both arms; ACS: acute coronary syndrome;
LDL-C: low-density lipoproteins cholesterol; ALT:
alanine aminotransferase; AST: aspartate aminotransferase |
*P-value was obtained using Fisher’s Exact test;
**P-value was obtained using Chi-square test;
aMissing data for ~60% of study
participants in both arms; ACS: acute coronary syndrome;
LDL-C: low-density lipoproteins cholesterol; ALT:
alanine aminotransferase; AST: aspartate aminotransferase |
*P-value was obtained using Fisher’s Exact test;
**P-value was obtained using Chi-square test;
aMissing data for ~60% of study
participants in both arms; ACS: acute coronary syndrome;
LDL-C: low-density lipoproteins cholesterol; ALT:
alanine aminotransferase; AST: aspartate
aminotransferase |